Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing

Author(s):
Leeneer, K. de; Bockstal, M. van; Brouwer, S. de; Swietek, N.; Schietecatte, P.; Sabbaghian, N.; Ende, J. van den; Willocx, S.; Storm, K.; Blaumeiser, B.; Asperen, C.J. van (0000-0002-1436-7650); Wijnen, J.T. (0000-0003-2805-6922); Leunen, K.; Legius, E.; Michils, G.; Matthijs, G.; Blok, M.J.; Gomez-Garcia, E.; Paepe, A. de; Tischkowitz, M.; Poppe, B.; Claes, K.
Published
2012
Publication type
Article / Letter to editor
Hereditary breast and ovarian cancerRAD51CGermline mutationsBRCA1/2-negative
Date issued
2012-05-31
Language
English
Is part of
Breast Cancer Research and Treatment (2012), Vol. 133, no. 1, p. 393-398
hdl
1887/97991
doi
10.1007/s10549-012-1998-4